Medical guidelines regarding routine prostate-specific antigen (PSA) screening after age 70 often suggest caution because slow-growing prostate cancers diagnosed later in life may never become clinically significant or threaten a patient's natural lifespan. Routine screening in older populations can lead to overdiagnosis and overtreatment, exposing patients to the risks of incontinence and impotence from unnecessary interventions. However, individual health status, life expectancy, and patient preferences heavily influence whether a physician continues ordering routine PSA checks past age 70.